BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Med-tech outlook 2026
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Sunday, March 15, 2026
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Sep. 1, 2020
View Archived Issues
AP-1 and antidepressant action
Read More
Candida auris: mostly, nothing wrong
Read More
BeiGene and Singlomics sign license agreement for SARS-CoV-2-neutralizing antibody drug candidates
Read More
Immutep and Monash University receive grant from ARC to extend their LAG-3 project
Read More
FDA accepts IND application for phase IIa study of SPR-720
Read More
Discovery of novel HIF-PHD2 inhibitors for the treatment of anemia
Read More
First preclinical data presented for ATI-2173, a novel compound for treating HBV
Read More
French investigators patent new acetylcholinesterase reactivators
Read More
Results from first clinical trial of KB-174 in patients with well-compensated cirrhosis
Read More
Merck KGaA synthesizes new KIT mutant inhibitors
Read More
Ardelyx divulges glycyrrhetinic derivatives for hyperkalemia
Read More
Maruho identifies new BRD4 inhibitors
Read More
New TYK2 ligands presented by Ventyx Biosciences
Read More
Regulatory loop modulates innate-adaptive immune crosstalk in fever
Read More
Anti-vimentin monoclonal antibody hzVSF-v13 safe in phase I trial
Read More
HH-2853 enters first-in-human study for NHL and advanced solid tumors
Read More
Oxurion begins phase II study of THR-149 for DME
Read More
Phase III study of Kevzara in severely or critically ill COVID-19 patients misses primary endpoint
Read More
FDA clears Sound Pharmaceuticals to begin phase II studies with ebselen in COVID-19
Read More
FDA approves Xaracoll for acute postsurgical pain relief following open inguinal hernia repair
Read More
GSK and Vir begin phase II/III study of anti-SARS-CoV-2 monoclonal antibody VIR-7831
Read More
Prevail opens phase I/II study of PR-006 in frontotemporal dementia with progranulin mutations
Read More
European approval for Imfinzi as first-line treatment of extensive-stage small cell lung cancer
Read More
Embera begins phase II study of EMB-001 for cocaine use disorder
Read More
FDA clears IND for clinical development of OMS-906 for PNH
Read More
